IL6 and juvenile idiopathic arthritis: More recently, the evidenced based choice of biologics for JIA has expanded to include other anti-TNF therapies [e.g., adalimumab and infliximab (off-label use in Europe)] as well as alternative cytokine blockade for both systemic and polyarticular JIA (e.g., the IL-6 inhibitor tocilizumab and IL-1 blockade with anakinra) [9].